RES MILITARIS Social Science Journal

MOLECULAR STRUCTURE DETERMINATION OF 1-METHYLNEPHTHLENE With β-CYCLODEXTRIN INCLUSION COMPLEXES USING NMR SPECTROSCOPY

Mandavi Mishra, Dinesh Kumar Sharma, Manisha Sharma

[1]Institute of Applied Sciences, Mangalayatan University, Beswan, Aligarh-202146

Corresponding Author: Madhvi

Corresponding Author's Email Id: mismandavi25@gmail.com

Abstract - DFT is a decisive tool for determining the structure of small organic molecules. The inclusion properties of 1-methylnephthlene with β-Cyclodextrin were examined in this study. Several methods were used to further analyse the inclusion compound that was finally prepared. The results indicated that the peak position of β-CD shifted after inclusion, and the ratio of β-CD to 1-methylnephthlene was determined to be 1:1.

Keywords: β-cyclodextrin, [1]H-NMR, 1-methylnephthlene, DFT.

1 INTRODUCTION

Drug stability is crucial for the pharmaceutical sector. Creating settings or systems that stabilise medications so that they may be safely administered to a patient is likewise a major scientific problem. Numerous techniques that depend on managing external factors (such as pH and temperature) that might change over time have been put forth. [1,2]. Drugs can be more robustly encapsulated in a media that shields them from chemical reactions. In this work, we investigate the potential of cyclodextrins as encapsulating agents using model systems. Cyclodextrins (CDs) are oligosaccharides made up of different quantities of glucose units connected by α-1,4 [3]. The sizes that are most frequently seen are the α-, β-, and γ -CD, or 6-, 7-, and 8-member cycles, respectively. Because of the CD structure, the molecule has a molecular size cavity, or "molecular bucket." Because hydroxyl groups line the cavity's rims, unsubstituted CDs are somewhat soluble in water; the cavity's contents, however, are quite hydrophobic. Due to these characteristics, the CDs have the special ability to combine with organic molecules in water to create host-guest inclusion complexes. [4]. The most widely recognized type of CD: guest complex is the socalled 1:1 perplexing, in which one Disc atom has one visitor particle inside its depression [4-6]. It is deeply grounded that such Album complexed species show compound and actual properties that might be very not the same as that saw in homogeneous arrangement [5-11]. These distinctions might be changes in item

type, item conveyance or pace of response. Specifically, rates might be expanded or diminished upon complexation, contingent on the kind of response and the reagents in question. Lately much exertion has been made to investigate and foster drug utilizations of Compact discs [11-18], including the readiness of an assortment of derivatized frameworks with better poisonousness profiles [12]. It has been called attention to that CDs show guarantee as medication stabilizers [1, 11, 19]. Drugs epitomized in 1:1 CD edifices frequently show decreased paces of response towards water-based reagents because of compartmentalization [1, 10, 19, 20]. Response restraint has additionally been seen with other, non-drug, visitors [7, 21-26] .Worked on substance security in CD host-visitor frameworks emerges from epitome. It makes sense that the more complete the embodiment, the more noteworthy the confinement of the visitor and the more completely safeguarded it will be. One potential methodology is to foster frameworks shaping higher-request buildings. By 'higher-request buildings' we allude to have visitor frameworks contained two Cd and one visitor (2:1 edifices) or two Compact disc and two visitors (2:2 buildings). There 2-Anthracene sulfonate and 2-anthracene carbonate structure 2:2 buildings with β-Album [27]. Nonetheless, it is higher request edifices of Compact discs with naphthalene and subordinates stand out. An early report from Ueno et al. [28] on the 2:2 complex of β-Disc with 1-naphthaleneacetate was trailed by a progression of articles from Hamai and, all the more as of late, Bohne et al. [24, 28] and Grabner et al. [29] have laid out that naphthalene and its subsidiaries promptly structure 2:2 buildings with β-Album assuming the naphthalene and Disc focuses are adequately high. These are areas of strength for somewhat with revealed development constants on the request for 4000 M−1 [30-32]. In most of these frameworks the presence of the 2:2 complex is shown by perception of naphthalene energized dimer (i.e., excimer) fluorescence. Different frameworks, for example, 6-bromo-2-naphthol and α-Compact disc, for instance, structure 2:1 host; guest edifices [33]. Data on the elements of higher request Disc buildings is restricted.

The current commitment presents results on the β-CD:1-methylnaphthalene framework under states of 1:1 complex development. Based on the properties of β-CD:1-methylnaphthalene, we have estimated the inclusion behaviour of beta-cyclodextrin as host and 1-methylnaphthalene guest using 1D NMR experiments.

2. EXPERIMENTAL ANALYSIS

2.1.Reagents: β-Cyclodextrin was purchased from Sigma-Aldrich and recrystallized twice before their use. 4 propyl phenol and other reagents were of analytical grade and used as commercially.

2.2. Inclusion Complex Synthesis

β-cyclodextrin and 1-methylnaphthalene phenol was taken and dissolved in doubled distilled water and methanol. After that, a solution of 1-methylnaphthalene and methanol was dropped into β-CD solution with stirring for 24 h at room temperature. At the end, an inclusion complex of 4-propylphenol with β-CD was obtained by filtration method [34]. The as obtained product was washed with methanol and water to clean the residual guest and host monomer respectively. Finally, it was dried in oven for about 48 h and further used for analysis purposes.

3. RESULTS AND DISCUSSION

3.1 ^{1}H-NMR Study

The NMR spectrum of the pure beta cyclodextrin, 1-Methylnaphthalene and inclusion complex was studied. The NMR spectrum of the inclusion compound exhibited a small shift in the peak position towards upfiled in the cavity protons of β-CD (Ulaş 2020; Do et al., 2022). A change in observed was observed in H-3 and H-5 protons in comparison to other protons. The shifting in the NMR peaks of cavity of β-CD was due to the presence of π-electron rich benzene ring and also due to the anisotropic.



Fig. 2.1 ^{1}H-NMR spectrum of cyclodextrin

After inclusion, it was observed that the β-CD protons peaks shifted in the inclusion compound[35].The chemical shift changes at H-3 and H-5 protons, showed maximum shielding compared to others protons. The inclusion spectrum (Fig. 2.1) showed that the compound 1-Methylcyclodextrin was successfully incorporated into the cavity of beta cyclodextrin and formed a well known compound. Further, the mocking docking study was also performed in order to confirm the inclusion [36].



Fig. 2.2 ^{1}H-NMR spectrum of pure and inclusion complex

3.2 Molecular docking studies

The molecular spectrum was performed in order to explain the orientation of guest molecule (1-Methylnaphthaldene) into host molecule (β-CD). This analysis was performed using Genetic Algorithm in Auto dock 4.2.6 programme in which host molecule is considered as a fixed residue and guest molecule is flexible. The Gasteiger charge was developed on host molecule while charge on guest molecule was added automatically and the most stable conformation was obtained from the software which are shown in Fig.2.2. The docking analysis showed that the guest molecule is successfully embedded inside the cavity of beta cyclodextrin.



Molecular docking image of inclusion complex of 1-Methylnaphthaldene and Cyclodextrin

4 CONCLUSION

Thus, this analysis showed that the guest molecules 1-Methylnaphthalene was easily embedded inside the cavity of host molecule. In this was both the molecule showed a well-known host-guest interaction and the results were also supported this interaction.

REFERENCES

1. T. Loftsson and M.E. Brewster: *J. Pharm. Sci.* 85, 1017 (1996).
2. G. Thomas: *Medicinal Chemistry: an Introduction*, J. Wiley & Sons, Toronto (2000).
3. W. Saenger, J. Jacob, K. Gessler, T. Steiner, D. Hoffmann, H. Sanbe, K. Koizumi,
4. S.M.Smith, and T. Takaha: *Chem. Rev*. 98, 1787 (1998).
5. K.A. Connors: *Chem. Rev.* 97, 1325 (1997).
6. O.S. Tee: *Adv. Phys. Org. Chem*. 29, 1 (1994).
7. T. Nagai: Comprehensive Supramolecular Chemistry, Vol. 3, Pergamon/Elsevier: Oxford (1996).
8. C.H. Evans and T. Gunnlaugsson: *J. Photochem. Photobiol. A: Chem.*78, 57 (1994).
9. R. Breslow: *Acc. Chem. Res*. 28, 146 (1995).
10. P. Bortolus and S. Monti: In D.C. Neckers, D.H. Volman and G. von Bünau (eds.), *Advances in Photochemistry*, John Wiley & Sons, New York (1996), Vol. 27, p 1.
11. M. Partyka, H.A. Bao, and C.H. Evans: *J. Photochem. Photobiol.A:Chem*. 140, 67(2001).
12. N. Funasaki, S. Ishikawa, and S. Neya: *J. Pharm. Sci*. 90, 740 (2001).
13. K. Uekama, F. Hirayama, and T. Irie: *Chem. Rev*. 98, 2045 (1998).
14. V.J. Stella, V.M. Rao, E.A. Zabbou, and V. Zia: *Adv. Drug Delivery Rev*. 36, 3 (1999).

15. T. Irie and K. Uekama: *Adv. Drug Deliv. Rev*. 36, 101 (1999).
16. D.C. Bibby, N.M. Davies, and I.G. Tucker: *Int. J. Pharmaceutics* 197,1 (2000).
17. T. Loftsson, A. Magnusdottir, M. Masson, and J.F. Sigurjonsdottir: *J.Pharm. Sci*. 91, 2307 (2002).
18. J. Luengo, A. Aránguiz, J. Sepúlveda, L. Hernández, and C. Von Plessing: *J. Pharm. Sci*. 91, 2593 (2002).
19. V.M. Rao and V. Stella: *J. Pharm. Sci*. 92, 927 (2003).
20. M. Masson, T. Loftsson, S. Jonsdottir, H. Fridriksdottir, and D.S. Petersen: *Int. J.Pharmacutics* 164, 45 (1998).
21. T. Loftsson: *Drug Stability* 1, 22 (1995).
22. M.V. Encinas, E.A. Lissi, and A.M. Rufs: *Photochem. Photobiol*. 57,603 (1993).
23. C.H. Evans, S. De Feyter, L. Viaene, J. van Stam, and F.C. De Schryver: *J. Phys. Chem*. 100, 2129 (1996).
24. J. van Stam, S. De Feyter, F. C. De Schryver, and C.H. Evans: *J. Phys.Chem*. 100, 19959 (1996).
25. T.C. Barros, K. Stefaniak, J.F. Holzwarth, and C. Bohne: *J. Phys.Chem. A* 102, 5639 (1998).
26. M. Christoff, L.T. Okano, and C. Bohne: *J. Photochem. Photobiol. A:Chem*. 134, 169 (2000).
27. C.H. Evans, M. Partyka, and J. van Stam: J. *Inclusion Phenom*. 38, 381 (2000).
28. T. Tamaki, T. Kokubu, and K. Ichimura: Tetrahedron 43, 1485 (1987).
29. A. Ueno, K. Takahashi, and T. Osa: J. Chem. Soc., Chem. Commun.921 (1980).
30. S. Hamai: *Bull. Chem. Soc. Jpn*. 55, 2721 (1982).
31. S. Hamai, and N. Mononobe*: J. Photochem. Photobiol A: Chem*. 91,217 (1995).
32. R.S. Murphy, T.C. Barros, B. Mayer, G. Marconi, and C. Bohne: *Langmuir* 16, 8780 (2000).
33. G. Grabner, K. Rechthaler, B. Mayer, and G. Kohler: *J. Phys. Chem.A* 104, 1365 (2000).
34. Y. Sueishi, N. Inazumi, and T. Hanaya: *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, *64*, pp.135-141. 2009.
35. Ali et al., 2007; Sharma et al., 2020).
36. Shailajha et al., 2014; Sharma et al., 2020; Imtiaz et al., 2022; Hamai et al., 1998).